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Abstract
Background: To assess the frequency of IMLN recurrence, its associated risk factors with disease-free interval (DFI)
and its predicting factors on overall survival time.
Methods: 133 cases of breast cancer IMLN recurrence were identified via the computerized CT reporting system
between February 2003 and June 2008, during which chest CT for patients with breast cancer (n = 8867) were
performed consecutively at Cancer Hospital, Fudan University, Shanghai, China. Patients’ charts were retrieved and
patients’ characteristics, disease characteristics, and treatments after recurrence were collected for analysis. The
frequency was 1.5% (133/8867).
Results: IMLN recurrence was presented as the first metastatic site in 121 (91%) patients while 88 (66.2%) had
other concurrent metastases. Typical chest CT images included swelling of the IMLN at the ipsilateral side with
local lump and sternal erosion located mostly between the second and third intercostal space. The median
disease-free interval (DFI) of IMLN recurrence was 38 months. The independent factors that could delay the IMLN
recurrence were small tumor size (HR 0.5 95%CI: 0.4 - 0.8; p = 0.002), and positive ER/PR disease (HR 0.6, 95% CI:
0.4 - 0.9; p = 0.006). The median survival time after IMLN recurrence was 42 months, with a 5-year survival rate of
30%. Univariate analysis showed four variables significantly influenced the survival time: DFI of IMLN recurrence
(p = 0.001), no concurrent distant metastasis (p = 0.024), endocrine therapy for patients with positive ER/PR
(p = 0.000), radiotherapy (p = 0.040). The independent factors that reduced the death risk were no concurrent
distant metastases (HR: 0.7, 95% CI: 0.4 - 0.9; p = 0.031), endocrine therapy for patients with positive ER/PR status
(HR: 0.2, 95% CI: 0.1 - 0.5; p = 0.001) and palliative radiotherapy (HR: 0.3, 95% CI: 0.1- 0.9; p = 0.026).
Conclusions: The risk of IMLN recurrence is low and there are certain characteristics features on CT images. ER/PR
status is both a risk factor for DFI of IMLN recurrence and a prognostic factor for overall survival after IMLN
recurrence. Patients with only IMLN recurrence and/or local lesion have a good prognosis.
Background
The significance of internal mammary lymph node
(IMLN) as a second lymph node basin in breast cancer
where 8%~37% tumors drain to IMLN while 1%~5% of
tumor exclusively drain to the IMLN had been recog-
nized as a major prognostic factor historically [1-5]. It
was reported that 54% of central and inner quadrant
tumors and 18% lateral quadrant tumors were associated
with positive IMLN while 44% of cases with positive
axillary lymph nodes (ALN) had positive IMLN [6].
However, extended radical mastectomy that included
removal of IMLN was abandoned in the 1970s, both as
as t a g i n gp r o c e d u r eb e c a u s eo fal o wr a t eo fI M L N
metastases in the absence of concomitant ALN metas-
tases, and as a therapeutic procedure because removal
of all IMLN did not improve the prognosis. IMLN
involvement was found to be 4% to 65% during surgery,
8% to 27% during sentinel node biopsy, and 13% to 37%
on lymphoscintigraphy [1-5,7-10]. There was no local
control or survival benefit comparing extended radical
mastectomy (EM) to radical or modified radical mastect-
omy while more patients underwent EM experienced
surgical trauma and pleura-related complications
[11-14]. Yet, renewed interest has been observed for the
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alists’ Collaborative Group (EBCTCG) meta-analysis
that had established the importance of local-regional
control on long- term survival [15].
Following surgery, systemic adjuvant chemotherapy is
indicated in selected cases of localized disease based
upon prognostic risk factors. All patients with hormone
receptor-positive tumors should be considered for adju-
vant endocrine therapy lasting for at least 5 years.
Radiation of the chest wall and regional lymph nodes is
suggested following mastectomy in selected high-risk
patients. However, the value of IMLN irradiation with-
out ignoring the risk of cardiac morbidity in the subset
of patients with positive IMLN remains unclear pre-
sently while the prognostic significance of IMLN recur-
rences were scarce and controversial. Therefore, we
undertake the initiative to review all the patients pre-
sented with IMLN recurrence at our institution in order
to understand the characteristics associated with IMLN
and its predicting influenceo nt h ep r o g n o s i so fb r e a s t
cancer so that we might have a better understanding in
decision making for the most appropriate management
for patients who had undergone radical or modified
radical mastectomy. The aim of this study was to assess
t h ec h a n c eo fI M L Nr e c u r r e n c ei nas i n g l ei n s t i t u t i o n ,
its associated risk factors with disease-free interval (DFI)
and its predicting factors on overall survival time. A sta-
tistical analysis of a series of 133 breast cancer patients
with IMLN recurrences is presented.
Methods
IMLN recurrence in our study was defined as a soft
nodule with a diameter of 1 cm or larger adjacent to the
internal mammary vessels within the first through sixth
parasternal anterior intercostal space on spiral chest CT
scan and/or confirmed by cytology. Surgical manage-
ment usually performed at our center for patients with
primary breast cancer included modified and radical
mastectomy. Adjuvant chemotherapy for four to six
cycles of cyclophosphamide, methotrexate, and 5-fluor-
ouracil (CMF), cyclophosphamide, epirubicin, and 5-
fluorouracil (CEF) and CEF followed by docetaxel are
usually given for patients with node-positive disease or
at high risk despite having node-negative disease. Adju-
vant radiotherapy at a dose of 45-50 Gy delivered to
fields including chest wall and supraclavicular area with
a 10-Gy boost to tumor bed using targeted fields of
electrons are recommended for postmastectomy patients
with primary tumor size greater than 5 cm, 4 or more
positive axillary lymph nodes, or positive pathologic
margins. Adjuvant endocrine therapy was given for
patients with ER/PR positive tumors while trastuzumab
was not available for patients with HER-2 positive dis-
ease then. Patient was followed-up every 3 months after
primary surgery with documented physical examination,
every 6 months for ultrasonic examination, every 12
months for conventional CT-scan further spiral chest
CT scan if indicated.
To identify patients with IMLN recurrence, we
reviewed all chest spiral CT (computed tomographic)
reports covering a 5-year span from Feb 2003 through
June 2008 when CT reports were recorded by computer
at Cancer Hospital of Fudan University, Shanghai,
China, which served a population of almost half million.
All CT examinations were performed using a 40-row
helical CT scanner operated at 120 kV and 100 mAs,
with a maximized 45 × 45 cm field of view, a 512 × 512
matrix, and the table speed of 1.53 mm/0.5 seconds
(Somatom-40-row, Siemens Medical, Germany). CT
images were obtained using consecutive 5 mm-thick CT
scanning from the supraclavicular region to the top of
diaphragm with breath holding. Each CT scan which
reported internal mammary lymph node enlargement
was reviewed again by two radiologists for the confirma-
tion of clinically apparent IMLN recurrence.
The frequency of IMLN recurrence in this series was
1.5% (133/8867) after radical (n = 59) or modified radi-
cal mastectomy (n = 74). The primary surgery time was
between August 1988 and June 2007, the median sur-
gery time was Mar 2003. Patients who received primary
extended radical mastectomyw e r ee x c l u d e df r o mt h i s
study. IMLN status was not evaluated by sentinel LN
biopsy.
The median age at surgery was 57 years, with 78
(58.6%) patients being postmenopausal. The median pri-
mary tumor size was 2.5 cm (range: 1-7 cm), among
which 31.6% (n = 42) was ≤ 2 cm, 63.2% (n = 84) was
between 2 cm to 5 cm, and 5.2% (n = 7) > 5 cm. Num-
ber of ALN involvement was negative in 46.6% (n = 62)
patients, 1~3 in 32.3% patients (n = 43), and ≥4i n
21.1% patients (n = 28). According to 6
th AJCC staging
manual, 17 (12.8%) patients had stage I, 89 (64.4%) had
stage II, and 29 (21.8%) had stage III disease. 78 (58.6%)
patients were ER/PR positive. 29 (21.8%) had HER-2
positive disease (HER-2 positive was defined as +++ by
IHC method or FISH positive). The most common his-
tological type was invasive ductal carcinoma, with 46%
of the tumors located at the areola and inner quadrant
area.
After primary surgery, 124 (93.2%) patients received
adjuvant chemotherapy. Only 15.8% (21/133) received
adjuvant radiotherapy due to worrisome of the toxicity
of radiotherapy. All patients with ER/PR positive tumors
received adjuvant endocrine therapy (73 of 78 patients
received tamoxifen 20 mg daily, another 5 patients
received aromatase inhibitor). The median follow-up
time was 52 months (range: 10-246 months). All
patients’ characteristics were listed in Table 1.
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sent with recurrent disease at a more serious condition
due to poor compliance. All 133 patients were evaluated
for distant metastases using abdominal CT/MRI and
bone scan after the diagnosis of IMLN recurrence. The
types of therapy right after IMLN recurrence were
recorded. Endocrine therapy was most commonly used
for patients with ER/PR positive disease or at low risk of
rapidly progressive disease. Patient with ER and PR
negative, life-threaten condition or multiple metastatic
sites often received chemotherapy. Radiotherapy was
given either as initial or palliative treatment based on
patients’ disease presentation.
DFI of IMLN recurrence was calculated from the pri-
mary surgery to IMLN recurrence. The overall survival
time was calculated from the IMLN recurrence until
death or last follow-up. Actuarial curves were compared
by the two-tailed log-rank test and difference of p ≤
0.05 was considered significant. The independent prog-
nostic significance of variables on the events and survi-
val, proved to be significant factor in univariate analysis,
was tested in proportional hazards regression models
described by Cox. Survival analysis was carried out
using life-table and Kaplan-Meier method. The esti-
mates of the models are given as hazard ratio (HR) with
95% confidence intervals (95% CI).
Written informed consent was obtained from all
patients at the time of admission. The study had been
approved by the Fudan University Cancer Hospital Ethic
Committee for Clinical Investigation. Patients’ charts
were retrieved and patients’ characteristics, disease char-
acteristics, and initial treatments after IMLN recurrence
and patients’ survival were collected for analysis.
Results
Characteristics of IMLN recurrences
Clinical characteristics
Among the 133 patients, IMLN recurrence was pre-
sented as the first metastatic site in 121 (91.0%) patients,
only 12 had other sites of metastases prior to IMLN
recurrence. 88 (66.2%) patients had other concurrent
metastasis sites, 45 patients had isolated IMLN recur-
rence, of whom 23 developed distant metastases later.
There were 48 cases (36.1%) with ipsilateral visible soft
tissue mass beside the sternum, among which cytology
examination had been presented for 33 patients, all con-
firmed recurrence. There were 20 (15.0%) cases with
localized skin involvement with painful presentation.
Imaging of chest spiral CT scan
The typical CT-scan presentation was enlargement and
swelling of IMLN located on the ipsilateral side with the
formation of a local lump and sternal erosion (Figure 1).
Median enlarged nodal size was 2.5 cm (range: 1.0-9.0
cm). The majority of the cases presented with lympha-
denopathy traversing one to two anterior intercostal
spaces, being 48.1% and, 33.9%, respectively. Most nodal
enlargement was located at the second and third inter-
coastal space, being 67.7% and 19.5%, respectively. Iso-
lated lymphadenopathy in the fifth spaces was not
observed. About half of the cases with IMLN recurrence
occurred at multiple levels and were most common in
the second or third intercoastal spaces. Sternal erosion
occurs in 64.7% patients. The characteristics of the ima-
ging findings were presented in Table 2.
Table 1 Patient Characteristics
Patients
Characteristic N %
Age (years)
Median (range) 47 (23-72)
Menopausal stastus
Premenopausal 55 41.4
Postmenopausal 78 58.6
Histologic type
Invasive ductal carcinoma 125 94.0
Invasive lobular carcinoma 5 3.8
Medullary carcinoma 3 2.2
Primary tumor location
Areola and inner area 61 45.9
Outer area 72 54.1
Primary tumor size (cm)
Median (range) 2.5 (1-7)
≤2 42 31.6
>2 91 68.4
Anxillary lymph node (ALN)
negative 62 46.6
positive 71 53.4
TNM stage
I - II 104 78.2
III 29 21.8
ER/PR status
Positive 78 58.6
Negative 55 41.4
HER-2 status
Positive
& 29 19.5
Negative 104 80.5
Adjuvant chemotherapy
Yes 124 93.2
No 9 6.8
Adjuvant radiotherapy #
Yes 21 15.8
No 112 48.2
&HER-2 positive was defined as +++ by IHC method and/or FISH positive.
#Adjuvant radiotherapy field included chest wall and supraclavicular area, and
10-Gy boost was delivered to the tumor bed
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The median DFI of IMLN recurrence was 38 months
(range: 4-241 months). Tumor size, ER/PR status, adju-
vant radiotherapy for T > 5 cm were variables that sig-
nificantly influenced the DFI of IMLN recurrence (Table
3). The DFI for patients with primary tumor size ≤ 2
cm and > 2 cm was 49 and 33 months, respectively (p =
0.021). The DFI for patients with positive and negative
ER/PR was 50 and 32 months, respectively (p = 0.020).
For patients with T > 5 cm, DFI was 56 months and 21
months for those with or without adjuvant radiotherapy,
respectively p = 0.018. All the following tested variables
had no influence on the DFI of IMLN recurrence:
menopausal status, primary tumor location, number of
ALN involvement, post-surgery TNM stage, HER-2 sta-
tus, adjuvant chemotherapy, adjuvant radiotherapy for ≥
4 positive ALN.
Three factors were tested in multivariate analysis:
tumor size, ER/PR status, adjuvant radiotherapy for T
>5 cm. The result showed that the DFI of IMLN recur-
rence was independently influenced by tumor size (HR
0.5, 95% CI: 0.4 - 0.8; p = 0.002), and ER/PR status (HR
0.6, 95% CI: 0.4 - 0.9; p = 0.006) (Table 3).
Prognostic factor after IMLN recurrence
The median survival time after IMLN recurrence was 42
months, and the 5-year survival rate was 30% for all
patients. The 5-year survival of patients without concur-
rent other sites metastasis was 43%. The results of
univariate analysis of the tested prognostic variables are
shown in Table 4. After univariate analysis, four predict-
ing variables significantly influenced the survival time.
DFI of IMLN recurrence (< 2 years vs ≥ 2 years, p =
0.001), concurrent metastasis (none and local vs distant
metastases, p = 0.024), endocrine therapy for patients
with positive ER/PR (yes vs no, p = 0.000), radiotherapy
(yes vs no, p = 0.040). Whether IMLN presented as first
or subsequent metastatic site, the size of recurrent
IMLN and the type of first-line chemotherapy had no
influence on the overall survival time. The median over-
all survival time for patients with isolated IMLN recur-
rence was 63 months, patients with concurrent local
metastasis 51 months (p = 0.432). The median overall
survival time when both isolated IMLN and with local
metastases was combined was 61 months, while that of
concurrent bone or visceral metastasis (lung or liver or
brain, etc) was 32 months. Univariate analysis also
showed that the presence of concurrent distant metas-
tases (p = 0.010) predicted the survival time (Table 4).
The four factors proved to be significant in univariate
analysis were tested by multivariate analysis (shown in
Table 4). The following independent factors that
reduced the risk of death were no concurrent distant
metastases (HR: 0.7, 95% CI: 0.4- 0.9; p = 0.031), pre-
sence of endocrine therapy for patients with positive
E R / P R( H R :0 . 2 ,9 5 %C I :0 . 1-0 . 5 ;p = 0.001), presence
of sequential radiotherapy delivered to the IMLN area
(HR: 0.3, 95% CI: 0.1- 0.9; p = 0.026).
Figure 1 CT image demonstrated internal mammary node forming a mass with a diameter of 3 cm at a level of the second right
anterior intercostal space accompany by sternal erosion.
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This is the largest report of IMLN recurrences up to
date. The frequency of IMLN recurrence was rare
[16,17], 1.5% in our series, and even rarer among
patients with other cancer types. But it was characteris-
tic recurrence site for the patients with breast cancer,
only two patients with other solid tumors, both male,
were noted to have IMLN metastases on CT scan in our
institution, one suffered from malignant melanoma, and
the other rhabdomyosarcoma. Two independent factors
were found to delay IMLN recurrence among patients
with breast cancer: small tumor size, and positive ER
and PR status. Three independent factors were identified
to increase death risk: absence of endocrine therapy for
patients with positive ER/PR status, absence of palliative
radiotherapy and concurrent distant metastases.
The diagnosis of IMLN recurrence was based on the
clinical presentation and chest CT-scan [18]. Clinical
symptoms may include broad base parasternal swelling
with concomitant pain or skin involvement. Some
patients with IMLN recurrence were discovered on a
chest CT-scan during routine follow-up. The typical
CT-scan presentation was swelling of IMLN, usually
located at the ipsilateral side of the treated breast, with
a local lump and sternal erosion. About half of the
IMLN recurrence occured at multiple levels and were
most commonly seen in the second or third intercoastal
space. Most IMLN recurrence, 66.2% in this series, pre-
sented concurrently with other metastases sites, or were
followed by visceral metastasis similar to those of other
reports [19]. Therefore, once IMLN recurrence was
detected, a thorough re-staging workup was necessary to
evaluate the extent of the disease status.
Recurrence in the IMLN is rare, despite the fact that
these nodes are the second LN drainage basin of breast
cancer and are left untreated after surgery in most
patients. Tumor location, positive ALN, younger age,
and larger tumor size (>5 cm) had been reported as
high risk factors of tumor cells drainage to IMLN [8],
but the risk factors of IMLN recurrence had not been
clarified. Tumor size has been reported as a risk factor
not only for IMLN drainage but also for local recur-
rence [8,19,20]. Harris et al reported T2 tumor size (P =
0.004), and Stage II disease (P = 0.017) were associated
significantly with any regional lymph node recurrence
(including ALN, IMLN, supraclavicular lymph node).
Bijker et al reported the significant independent factors
were tumor size > 5 cm (measured by pathology) (p =
0.0002). Conflicting results have been reported regarding
the influence of ALN status on regional recurrence
[19,20]. Since all patients in our present study had
developed IMLN recurrence, factors that could influence
the DFI of IMLN recurrence instead of risk factors for
IMLN recurrence were evaluated. We concluded that
tumor size, not ALN status, could influence the interval
of IMLN recurrence.
Several studies reported that adjuvant treatment mod-
alities did not influence the risk of local recurrence after
breast-conserving surgery for early-stage disease [21-23].
However, adjuvant hormonal therapy was observed to
delay IMLN recurrence for patients with ER/PR positive
disease in our study. We postulated that different surgi-
cal methods and stage at presentation in our series may
contribute to the different conclusion. The finding in
our series that adjuvant radiotherapy could significant
delay the IMLN recurrence for patients with tumor size
> 5 cm, paralleled other studies on postmastectomy
radiation delivered to fields including IMLN, supraclavi-
cular, axillary, and chest wall, which demonstrated sig-
nificant decreased risk of locoregional recurrence in
high-risk breast cancer patients [24,25]. The significance
of adjuvant chemotherapy for delayed IMLN recurrence
could not be demonstrated in our study due to the fact
that the majority of patients included in this analysis
received adjuvant chemotherapy per NCCN guidelines.
Table 2 Characteristics of IMLN Recurrence
N%
Clinical
As first site of metastasis
Yes 121 91
No 12 9
Concurrent other sites metastasis
Yes 88 66.2
No 45 33.8
Visible soft tissue mass beside the sternum
Yes 42 31.6
No 91 68.4
Local pain and skin involvement
Yes 20 15.0
No 113 85.0
Imaging of CT scan
Size of IMLN recurrence (cm)
Median (range) 2.5 (1-9)
Anterior intercostal space
One 64 48.1
Two 45 33.9
Three 19 14.3
Four 5 3.7
Dominant location anterior intercostal space
First 15 11.3
Second 90 67.7
Third 26 19.5
Forth 2 1.5
Sternal erosion
Yes 86 64.7
No 47 35.3
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w h i l et h a tf o rt h o s ew i t hi s o l a t e dI M L Nr e c u r r e n c ew a s
43%. The results is similar to the findings of other stu-
dies on isolated local recurrence (IRL) of breast cancer,
ranging from 39-84%, IRL defined as new breast tumor,
chest wall recurrence, overlying skin recurrence, supra-
clavicular recurrence [21,26-29]. Since isolated IMLN
recurrence, longer DFI to IMLN recurrence, endocrine
therapy and radiotherapy were four favorable prognostic
factors for overall survival time, we propose that IMLN
recurrence should be included in the definition for ILR.
Time to ILR, the most frequently reported prognostic
factor for survival after local recurrence post breast-con-
serving surgery was also reported in our study for
IMLN recurrence after radical or modified radical breast
cancer surgery [28-30]. Endocrine therapy and radio-
therapy could prolong the survival time dramatically but
the benefit of chemotherapy was not observed in this
study. This may be due to the fact that patients indi-
cated for initial chemotherapy had a more advanced dis-
ease condition accompanying IMLN recurrence.
However, due to the rarity of IMLN recurrence, it
seemed difficult to initiate a prospective clinical trial to
evaluate the influence of systemic treatment and radio-
therapy on the survival.
The 2008 National Comprehensive Cancer Network
Clinical Practice Guidelines recommend consideration
of radiation therapy to internal mammary nodes for
patients with node-positive breast cancer after mastect-
omy or breast-conserving surgery, noting “substantial
controversy” on this topic. But as isolated IMLN recur-
rence is rare, it is unlikely that parasternal irradiation
will result in a significant reduction of the risk of clini-
cally apparent IMLN recurrence, based on the negligible
risk of IMLN recurrence without adjuvant radiotherapy.
T h u s ,w es t r o n g l ya d v o c a t et h a ti fI M L Ni sc l i n i c a lo r
Table 3 Univariate and multivariate analysis of DFI for IMLN recurrence
Factors N Univariate analysis Multivariate analysis
Median (m) p-value HR 95% CI p-value
Menopausal stastus 0.773 NS
Premenopausal 55 33
Postmenopausal 78 42
Primary tumor location 0.837 NS
Areola and inner area 61 38
Outer area 72 40
Tumor size(cm) 0.008* 0.5 0.4- 0.8 0.002*
≤24 2 4 9
>2 91 33
Axillary lymph node 0.070 NS
negative 62 43
positive 71 33
TNM stage 0.390 NS
I - II 104 38
III 29 29
ER/PR status 0.020* 0.6 0.4- 0.9 0.006*
Positive 78 50
Negative 55 32
HER-2 status 0.193 NS
Positive 29 26
Negative 104 42
Adjuvant chemotherapy 0.113 NS
Yes 124 36
No 9 41
Adjuvant radiotherapy for T >5c m 0.018* 0.9 0.6- 1.3 0.463
Yes 3 56
No 4 21
Adjuvant radiotherapy for ALN ≥4 0.949 NS
Yes 20 29
No 8 26
* p < 0.05
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Page 6 of 8pathological negative, it should be left untreated regard-
less of the status of axillary nodes.
Conclusions
In conclusion, our data show that the risk of IMLN recur-
rence is low and there are certain characteristics features
on CT images. ER/PR status is both a risk factor for DFI
of IMLN recurrence and a prognostic factor for overall
survival after IMLN recurrence. Patients with only IMLN
recurrence and/or local lesion have a good prognosis.
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